Clinical Evidence

The Minima Stent System is the only U.S. approved percutaneous device indicated for treating infant vascular stenosis.

Proven to be safe and effective for the treatment of coarctation of the aorta and pulmonary artery stenosis.

US Pivotal Minima Stent System
Growth Trial

A Multicenter Pivotal Study of the Minima Stent System for Vascular Stenoses in Neonates, Infants, and Young Children

Objective

The objective of the clinical investigation is to assess device performance and the clinical safety and effectiveness of the Minima Stent in neonates, infants, and young children requiring intervention for common congenital vascular stenosis (i.e., coarctation of the aorta and/or pulmonary artery stenosis) who are indicated for treatment.

Design

Prospective, multi-center, non-randomized treatment study with one arm.

Primary Efficacy Endpoints

  • Immediate Stenosis Relief

  • Freedom from surgical intervention

  • Maintenance of Stented Vessel Diameter

Primary Safety Endpoints

  • Freedom for procedure/device related SAEs

Patient Demographics

42

Number of
Patients treated

9 months

Median Age at
time of implant

7.6 kg

Median Weight at
time of implant

259 days

Median Time to
first re-expansion

At the time of data lock

Number of Patients Treated by Lesion Location

Key Results

LPA Stenosis

Recurrent Aortic Coarctation

Additional Clinical Evidence

Supporting evidence from Renata and investigator sponsored studies

May 12, 2024

Results of the multicenter early feasibility study (EFS) of the Renata Minima stent as treatment for branch pulmonary artery stenosis and coarctation of aorta in infants.

Read Full Study

May 4, 2021

Preliminary testing and evaluation of the Renata Minima stent, an infant stent capable of achieving adult dimensions.

Read Full Study

Investigator Sponsored Studies

Renata Medical supports Investigator Sponsored Research (ISR) studies that advance our
mission to improve the lives of children battling congenital heart defects.

Contact Us For More Info

† Through 6-month follow-up data lock